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ABSTRACT 
Hydrophilic polymer matrix systems (HPMSs) are a highly relevant tool for drugs delivery whose bioavaila-
bility is impaired by low hydrosolubility. Besides this, when associated with nanoparticles these systems can 
provide better control over release profile of the active drug, maintaining the posology. Since polyvinylpyr-
rolidone (PVP) and zinc oxide (ZnO) are safe materials for use in the human body, we studied the effects of 
ZnO nanoparticle ratios on the characteristics of PVP matrix. For that purpose, nanocomposites were pre-
pared by solution casting method and characterized by X-ray Fluorescence (XRF), Fourier Transform Infra-
red (FTIR), Thermal Gravimetric Analyses (TGA), Differential Scanning Calorimetry (DSC), X-ray Diffrac-
tion (XDR) and Low-field Nuclear Magnetic Resonance (LF-NMR) technique, using relaxometry. We also 
analyzed the effects of the system on two broad-spectrum antimicrobial drugs. The characterization results of 
the new materials indicate good interaction of the nanoparticles with the polymer, and this fact suggests that 
these new materials may have a retarding effect on drug release. The results also showed no disruptive inter-
action of the matrix system important to the action of the antimicrobials. 
Keywords: Polymer, Nanotechnology, Drug delivery, ZnO. 
1. INTRODUCTION 
Drugs administered orally in solid form can be classified according to the release mechanism of the active 
ingredient in the body. By tailoring for the pharmaceutical formulation, the release can be conventional or 
modified, in which the availability of the drug is delayed or sustained. In this case, the systems are consid-
ered to be time-dependent, able to maintain blood concentrations at therapeutic concentrations for longer 
periods [1], [2] 
           The use of polymers to modulate drug release in specific situations is related directly to the intrinsic 
properties of the polymer, such as the ability to form microporous or semipermeable structures, swelling in 
water and complexation with drugs. These characteristics can give rise to systems with various morphologies 
for modulating drug release, including hydrophilic polymer matrix systems [3]. 
           Although the polymers already have be shown to have wide pharmacotechnical applications, recent 
research has indicated that the efficiency in controlling drug release can be enhanced by the incorporation of 
nanoparticles in the polymer matrix, forming polymer nanocomposites [4]. These nanocomposites can act as 
efficient complexes barrier that inhibit the diffusion of the drug permeating these materials layer by layers 
dispersed and distributed in the matrix, regulating the permeation to the body [5], [6];. Therefore, it is 
worthwhile learning the possible interferences or interactions of nanostructures with the system as a whole.         
            In this present study was observed the influence of zinc oxide (ZnO) nanoparticles on the structure of 
a hydrophilic matrix composed of polyvinylpyrrolidone (PVP), which is a polymer widely used in pharma-
ceutical applications. To assess the microstructural alterations of the proposed system on drug release, two 
antimicrobials were tested: trimethoprim and sulfamethoxazole, bacteriostatic agents normally employed in 
association. 
           Hydrophilic Polymer Matrix Systems (HPMSs) promote drug release due to the swelling of the poly-
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mer by the action of the water present in the fluids of the gastrointestinal tract, and then diffusion of the drug 
and/or erosion of the matrix, may occur. These parameters vary according to the physico-chemical properties 
of the polymer nanocomposites, after drug incorporation, as well as the kinetics and release control mecha-
nisms. The penetration of water through the matrix promotes transition of the polymer from a glassy state to 
swollen state as the intermolecular interactions between chains change. This reduces the polymer-polymer 
attraction forces, leading to more freedom conformational, allowing the drug to diffuse gradually making a 
tortoise way due to the presence of layers in the system [3], [7]–[10]. The swelling of hydrophilic matrixes 
due to the relaxation of the polymer chains when in contact with an aqueous medium is described as the for-
mation of “fronts", which delineate the different phases of the matrix [11]. 
           Polyvinylpyrrolidone is a polymer commonly used in pharmaceutical applications due to its actions 
for agglutination, disintegration, and especially PVP promotes of dissolution of drugs that have low water 
solubility. This last effect is attributed to the ability to form a porous polymer matrix structure when in an 
aqueous medium. This leads to a considerable increase in the drug’s contact surface with the dissolution me-
dium [12]. 
           PVP is a white or light yellow powder soluble in water and organic solvents. It is biocompatible and 
does not form crystalline structures (amorphous nature). Its molar mass is measured for commercial purposes 
in function of the Fikentscher value (K), derived from the viscosity of the solution [13]. The fact that the K 
value has a well-established relation with the expected molar mass of this polymer makes knowledge of this 
parameter relevant in determining the application of the material. Molar mass above 50,000 g/mol reduce the 
hydrosolubility of the PVP, increasing its viscosity. This justifies its use to modulate the release of drugs. 
           Polymers with similar characteristics and properties have been described regarding their bioadhesive 
properties, i.e., mucoadhesion capability. The bioadhesion phenomenon is not fully understood, but it is be-
lieved to involve three important kinetic steps: adsorption, spreading of the bioadhesive polymer material 
over the mucosa, and interpenetration of the chains of the polymer and mucosa. Therefore, the increase in the 
contact surface in function of high molar mass, as well as the ability to form hydrogen bonds and flexibility 
of the polymer chains, enables the interpenetration of the material by the main protein of mucus, allowing 
establishing the physical and chemical interactions[12]. 
           The chemical and physical properties make PVP’s use in nanocomposites attractive. This is a strategy 
employed in various pharmaceutical formulations, in which a hybrid composition is obtained from structures 
with a least one dimension having nanometric scale, well dispersed and distributed in a polymer matrix, to 
improve or totally alter the pharmacotechnical parameters. This allows designing the release profile, as well 
as directing the drug to the target organ or tissue, reducing the posology and/or toxicity of some drugs [9], 
[13]–[16]. 
           Thus, according to the exposed the present work was based on developing nanocomposites of 
PVP/ZnO to be used as an agent to drug delivery systems, for two drugs trimethoprim and sulfamethoxazole. 
The novelty of this work is the obtained systems and also the characterization of those, mainly employing 
nuclear magnetic resonance relaxometry that allowed understanding the behavior of the new materials. 
 
2. MATERIAIS E MÉTODOS 
2.1 MATERIALS 
In this work was used poly(vinylpyrrolidone) (PVP K30) from Sigma-Aldrich Chemistry as a matrix, zinc 
oxide (ZnO<100nm) from Sigma-Aldrich Chemistry as nanoparticle and sulfamethoxazole and trimethoprim, 
both from Virchow Laboratories, as drugs. 
2.2 PREPARATION OF THE SAMPLES 
The samples were obtained by two main steps: formation and milling of brittle films from dispersions in wa-
ter. Water was chosen as the solvent because it has good interaction with the polymer and enables obtaining 
brittle films, favoring milling to obtain a powder.  
            To obtain the materials films, 10% of PVP (w/v), the polymer mass was dissolved in water in a mag-
netic stirred at constant rate of 500 rpm for 3 hours. Then the solution was cast into Petri dishes, which were 
placed in an oven for 48 hours at 50 ºC to dry. 
           The films containing 10% (w/v) PVP and ZnO were obtained with varying concentrations of the na-
noparticle (0.25, 0.50, 0.75 and 1%, designated PZ025, PZ050, PZ075 and PZ100, respectively). For this, 
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PVP and ZnO were dispersed in water in a magnetic stirred for 3 hours at a constant rate of 500 rpm. The 
dispersions were casting into Petri dishes, which were also placed in an oven for 48 hours at 50 ºC to dry. 
           The same way was used to prepare the PVP/ZnO, and the two drugs; sulfamethoxazole and trime-
thoprim. The aim of this part was to improve the dispersion of these drugs in the matrix system due to the 
reduction of the chemical interactions of the pharmaceutical structures. The proportions between sulfameth-
oxazole and trimethoprim were maintained according to the commercial formulation, at 5:1. 
           In a first step, PVP and ZnO were dispersed in water in a magnetic stirring for 1.5 hours at 500 rpm.          
           The sulfamethoxazole was added manually and the system was kept under stirring for another 1.5 
hours. Then the dispersion was casting into Petri dishes, which were placed in an oven at 50 ºC for 48 hours 
to dry. The dispersion containing trimethoprim was prepared with the same parameters. The samples were 
designated PZ025ST, PZ050ST, PZ075ST and PZ100ST, these codes were created based in the initial letter 
of matrix (P), initial letter of zinc oxide (Z), following the percentage number of used of ZnO and initial let-
ter of each contained drug, S- sulfamethoxazole and T – trimethoprim. 
           After the complete solvent evaporation, the films were pulverized in a ball mill at 40 rpm for 40 
minutes. For the films containing sulfamethoxazole or trimethoprim, the milling also acted as a mixture step, 
since the drug-containing films were simultaneously added, respecting the concentrations of ZnO.  
 
2.3 CHARACTERIZATION 
The samples prepared was characterized by: 
X-Ray Fluorescence Spectroscopy: Samples were analyzed in a spectrophotometry using a 4kW rhodium 
tube, at voltage of 50 kV and current of 50 mA. The data were treated with the Rigaku software, RIX for 
Windows®. 
           Fourier-Transform Infrared Spectroscopy: A FTIR spectrometer was used coupled to a MIRacle® 
attenuated total reflectance (ATR) accessory. The spectra were obtained by the average of 120 consecutive 
scans, with resolution of 4cm-1, in the interval from 4000 to 400cm-1. 
           Thermogravimetric Analysis: The thermal degradation was observed from 25 to 700 ºC, with a heating 
rate of 10 ºC/min under nitrogen atmosphere. 
           Differential Scanning Calorimetry: The analyzes were carried out from 25 to 300 ºC, at a heating rate 
of 10 ºC/min in nitrogen atmosphere at 50 ml/min. 
           X-Ray Diffraction Analysis: the diffraction angle was 2θ registered from 2 to 50º at ambient tempera-
ture with a CuKα radiation. The data were treated with the OriginPro 8.5® and Fityk 9.8® programs. 
           Low Field Nuclear Magnetic Resonance Spectroscopy: A low-field NMR spectrometer was used, with 
18 mm probe for protons. The pulse sequence used to determine the proton spin-lattice relaxation time was 
inversion-recovery. The 90 degree pulse was automatically calibrated at 4.5 µs, 40 numbers of taus with 4 
points each, at 28 ºC. The WinFit® and the WinDXP® programs received with the NMR equipment were 
used to analyze the data. 
3. RESULTS AND DISCUSSION 
Pharmaceutical material need to have high purity, to minimize unexpected and undesirable biological effects, 
which can be caused by the presence of oxides or other substances that can interact and trigger organic re-
sponses. Therefore, XRF spectroscopy should be conducted before other tests are applied. The results are 
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ZnO Al2O3 0.02 0.07 
SO3 0.08 0.07 
Cl 0.02 0,04 
ZnO 578.9 99.8 
PVP Film Fe2O3 0.29 1.6 
NiO 0.26 0.5 
N 1.37 97.9 
 
 
           The ZnO solution showed a predominance of this oxide, confirming that the reagent was highly pure. 
Likewise, the polymer utilized, PVP, showed also be pure. In parallel to this analysis, FTIR spectroscopy was 
performed to corroborate the results of the composition of substances, confirming their structure. Figure 1 
shows the four main bands characteristic of PVP. At low frequency, a band can be seen at 2918 cm
-1
, refer-
ring to the C-H axial deformation of the cyclic chains. The bands at 1664 and 1284 cm
-1
 are attributed to the 
bifunctionality of PVP, C=O and C-N, respectively, both in axial deformation. These bands indicate key 
points of the architecture of the molecular structure, especially to reaffirm the amidic nature of this polymer, 
essential for interaction with drugs having low solubility in water. At 1422 cm
-1
, the axial C-C deformation 
between the carbon atoms of the ring can be seen. Figure 1, also contains the FTIR spectrum of the PVP Film. 
In this case, the analysis was carried out for comparison of the structures before and after processing. How-
ever, the method used was not able to significantly alter the molecule’s structure, since the transmittance (%) 
is observed in the same band, indicating the composition was unchanged, as expected. Analyzing the ZnO 
FTIR spectrum, no organic impurities were detected, although some bands can be observed near 2000 cm
-1
. 
These can be attributed to the O-H stretching caused by the presence of natural hydroxyl groups and humidi-
ty (Figure 1).  
 
 
Figure 1: FTIR of PVP, PVP Film and ZnO 
           Thermogravimetric analysis was used to evaluate the thermal stability of the polymer samples. Table 2 
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contains the degradation temperature obtained for the commercial PVP.  
 
Table 2: Thermal parameters of the Commercial PVP 
Sample Moisture Content (%) Tonset (
oC) Tpeak (
oC) Residue (%) 
Comercial PVP 6 407 434 2 
 
           The sample underwent a small initial weight loss of approximately 6% (w/w) at a temperature of 180 
ºC. This is generally attributed to the presence of volatile components and moisture. Since this is a highly 
hygroscopic polymer, this type of event is expected. The main weight loss occurred in a single degradation 
stage, at 407.4 ºC, considered to be the Tonset. This can be attributed to the rupture of important bonds for 
maintenance of the chain structure. The maximum degradation occurred at 433.7 ºC, where 50% of the deg-
radation process took place (T0.5). At the end of the process, 2% of the residue was observed. 
           All the analyses conducted with the samples following the PVP did not reveal significant variation in 
the degradation profile when compared with the unprocessed polymer (PVP Powder). The most relevant 
events are reported in Table 3. Although the values of each parameter are approximate, the results show little 
or very little influence of the nanoparticle in the nanocomposite. However, for total weight loss there was a 
gradual reduction in the percentage lost. The two drugs used were also submitted to thermogravimetric analy-
sis, revealing the onset of thermal degradation at 232.80 ºC for sulfamethoxazole and 252.81 ºC for trime-
thoprim. 
Table 3: TGA data  
SAMPLE TONSET  
(± 2 C) 
T0,5  
(± 2 C) 
RESIDUE  
(%) 
PVP Powder 407 434 2 
PVP Film 405 431 2 
PZ025 406 435 4 
PZ050 403 433 4 
PZ075 404 434 4 
PZ100 406 434 4 
 
           Differential scanning calorimetry was used to measure the variation of enthalpy in function of the 
temperature variation (∆T). Table 4 shows the glass transition values for the nanocomposites.  
Table 4: Glass transition temperature of materials  






           The glass transition temperature (Tg) could not be established from of PVP due to the level of struc-
tural disorganization. However, according to Haaf and collaborators [17], the Tg commonly reported for PVP 
K-30 is about 160 ºC, so the values found in analyzes of the nanomaterials showed a tendency to increase the 
Tg values. The nanocomposites presented a tendency to increase the Tg values according to the increase in 
the ZnO ratio up to 0.75% (increase of 15 ºC in the value of Tg) and showed a significant decrease for the 1% 
of ZnO incorporated, suggesting that there was good dispersion up to 0.75% of ZnO due to the intermolecu-
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lar interactions, promoting changes in the molecular mobility. 
           Figure 2 presents the XRD results, showing peaks in 30º to 50º related to ZnO. These peaks are in-
creased in the nanocomposites according to the increase of nanoparticle ratio. From these diffractograms was 
obtained the crystallinity degree (Xc) for the samples. PVP presents only an amorphous halo. Its nanocompo-
sites with ZnO (Figure 2) and the systems containing the drugs (Figure 3) presented same crystallinity degree 
(Tables 5 and 6), demonstrating that the interaction of the components was not sufficient to promote changes 
in the crystallinity degree. 
 
  
Figure 2: X-rays curves of samples before drugs incorporation 
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Table 5: Crystallinity degree (%) of the samples before drugs incorporation 
SAMPLE DEGREE OF CRYSTALLINITY (%) 
ZnO 85 







Table 6: Crystallinity degree (%) of the samples containing drugs 
SAMPLE DEGREE OF CRYSTALLINITY (%) 
ZnO 85 
PVP Film 22 






           The molecular dynamical behavior of the PVP and its nanomaterials were evaluated by NMR relaxo-
metry, through the proton spin-lattice relaxation time, which is a parameter sensitive the small changes in the 
intermolecular interaction and nanoparticle dispersion [6], [18], [19]. Firstly, the commercial PVP was ana-
lyzed and relaxation behavior was used to compare with the samples after ZnO incorporation, to observe the 
changes in the molecular dynamics, due to intermolecular interaction and ZnO dispersion, since the nanopar-
ticles has good dispersion and distribution in the PVP matrix.  
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Figure 4: Domain distribution of the relaxation times of the samples 
           Figure 4 shows the distribution curves of the relaxation time for PVP and the nanocomposites. All 
domains relaxation curves contain a small domain with lower amplitude, below 10 ms, referring to the pres-
ence of moisture due to the hydrophilic samples nature. The distribution of relaxation times curves for sam-
ples containing nanoparticles presented a similar pattern. It was noted that the addition of ZnO caused an 
alteration of the molecular dynamics of the PVP matrix, leading to changes in the values of relaxation times 
(Table 7) when compared to the pure polymer sample.  
Table 7: Relaxation time T1 determined from 1 exponential 
SAMPLE T1H (ms) 
PVP Powder 179 






            In PZ100 and PZ025 systems, a very subtle enlargement of the domains was observed in comparison 
with the polymer and also an increase in the relaxation time values, indicating the formation of a new materi-
al, containing good dispersion and distribution of the ZnO in polymer matrix, making the new hybrid materi-
al rigid. For PZ075 system, there was a small decrease in the values of relaxation times, although the base of 
the domains had similar width as the PVP Film, suggesting that the dispersion of the nanoparticles caused an 
increase in the system’s molecular mobility, but without achieving a better distribution. However, sample 
PZ050 presented a greater shift to shorter relaxation time value, along with narrowing of the domain relaxa-
tion curve. This is an indication that the nanomaterial presented higher molecular mobility comparing to PVP 
Film, and the dispersion and distribution of ZnO particles more homogeneous, generating a new material 
with good characteristics comparing to other composites and PVP. These characteristics come from the 
nanostructured organization of the particles in the matrix system. Thus, these results may suggest that PZ050 
system could be more adequate than the others when applied to fast drug release systems because present a 
low relaxation time, in other words this system needs less energy to release the drug and in the same way the 
PZ025 is adequate to drug slow release systems. In all characterizations showed in this work those samples 
present similar characteristics, though with opposite behavior of molecular mobility. The molecular mobility 
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is an important parameter to control the way and the velocity of drug release by erosion of the matrix and by 
drug diffusion. 
4. CONCLUSION  
The method used to obtain the nanomaterials do not change the crystallinity degree or thermal properties. 
This is a good aspect because allows keep the traditional compressed tablet drugs preparation. The addition 
of distinct concentrations of zinc oxide nanoparticles in PVP matrix formed hybrid materials with good dis-
persion and distribution in the PVP matrix as relaxation times shows. The results suggest that PZ025 and 
PZ050 systems are adequate to applied to slow and fast drug release systems, respectively. 
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